ResultsIQ › Latest results › Sahajanand Medical Technologies Limited
Sahajanand Medical Technologies Limited Q2 FY27 results deck summary
NSE: SMT · BSE: 545001
Results deck of 5 Nov 2026, summarised by AI from the filing.
Q2 FY27 revenue rose 24.7% to ₹3,734 mn with EBITDA up 36.6% to ₹656 mn and PAT up 26.6% to ₹265 mn, the highest-ever quarter.
Key takeaways
- Record quarter Q2 FY27 revenue was ₹3,734 mn (+24.7% YoY), EBITDA ₹656 mn (+36.6%) and PAT ₹265 mn (+26.6%), the highest-ever quarterly figures.
- No numeric guidance Management gave no numeric revenue or margin guidance, only priorities of richer product mix, vertical integration, plant utilisation and overhead control.
- Cash cycle The cash conversion cycle fell 16 days to 128 in H1 FY27 from 144 in FY25, on faster collections and leaner stock.
- RoW growth RoW revenue grew 37.1% YoY to ₹2,904 mn in H1 FY27, now 40.0% of revenue and the largest region.
Sahajanand Medical Technologies Limited Q2 FY27 results
As filed: Revenue ₹373 cr, EBITDA ₹65.6 cr, PAT ₹26.5 cr, EBITDA margin 17.6%.
Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹373 cr). Scored once a year-earlier consolidated quarter exists.
Sahajanand Medical Technologies Limited earnings call, investor presentation and press release summaries
Figures from the company's filings with NSE and BSE. Not investment advice.